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Abstract 
Melanoma risk prediction models could be useful for matching preventive interventions to 
patients risk. We developed a model incorporating clinical-assessed risk factors for incident 
first-primary cutaneous melanoma using unconditional logistic regression with backward 
selection on the Australian Melanoma Family Study (461 cases and 329 controls) and 
externally validated it using the Leeds Melanoma Case-Control Study (960 cases and 513 
controls). 
 
Candidate predictors included clinically-assessed whole-body naevi and solar lentigines, and 
self-assessed risk factors pigmentation phenotype, sun exposure, family history and history of 
non-melanoma skin cancer. We evaluated the predictive strength and discrimination of the 
model risk factors using odds per age- and sex-adjusted standard deviation (OPERA) and the 
area under curve (AUC), and calibration using the Hosmer-Lemeshow (H-L) test.  
 
The final model included the number of naevi ≥2mm in diameter on the whole body, solar 
lentigines on the upper back (a 6-level scale), hair colour at age 18 years and personal history 
of non-melanoma skin cancer. Number of naevi was by far the strongest risk factor; the 
OPERA was 3.51 (95% CI 2.71-4.54) in the Australian study and 2.56 (95% CI 2.23-2.95) in 
the Leeds study. The AUC was 0.79 (95% CI 0.76-0.83) in the Australian study and 0.73 
(95% CI 0.70-0.75) in the Leeds study. The H-L test p-value was 0.30 in the Australian study 
and <0.001 in the Leeds study.  
 
This model incorporating clinically assessed risk factors had good discrimination, and could 
be used by clinicians to stratify patients by melanoma risk for the targeting of preventive 
interventions. 
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Introduction 
Melanoma incidence has been increasing among fair-skinned populations, with the highest 
incidence rates in Australia, New Zealand, North America and Europe.1 Risk factors include 
sun exposure, sunbed use, common and dysplastic naevi, Fitzpatrick skin type I and II, 
freckle density, skin colour, eye colour, hair colour, family history and a number of 
susceptibility genes, with sun exposure recognized as the major environmental risk factor.2-5 
Australian primary care prevention guidelines recommend a stratified approach to melanoma 
prevention, which includes: (1) sun protection for people at average melanoma risk, (2) sun 
protection and clinical-skin examinations for people at increased melanoma risk; and (3) sun 
protection, clinical-skin examinations and self-skin examinations for people at high 
melanoma risk.6  
 
Risk prediction models provide a single personalised assessment of an individual’s risk based 
on a combination of melanoma risk factors rather than relying on multiple individual risk 
factors, and may assist clinicians in matching preventive interventions to risk levels.7 Many 
melanoma prediction models use self-assessed risk factors for reasons of feasibility, time and 
cost.8 However, individuals tend to underestimate their naevus counts,9 a d clinically-
assessed dermatological risk factors may improve model performance.10 We aimed to 
develop a model for incident first-primary cutaneous melanoma using both clinically- and 
self-assessed risk factors from the Australian Melanoma Family Study,11 and externally 
validate the model using the Leeds Melanoma Case-Control Study.12 
 
Materials and methods 
Study participants 
Paper_short report_model incorporating clinical risk factors_final 5 
Table 1 details the Australian and Leeds population-based case-control studies,11, 12 which 
shared measurement protocols. 
 
The Australian Melanoma Family Study is a population-based, case-control-family study.11 
Data were collected using self-administered and telephone-administered questionnaires, and 
skin examinations were conducted by dermatology trainees on 461 incident first-primary 
cutaneous melanoma cases and 329 controls from Brisbane, Sydney and Melbourne, 
Australia. Cases, diagnosed between July 2000 and December 2002 at ages 18-39 years, were 
identified from state cancer registries. Controls were identified from the electoral roll 
(registration to vote is compulsory in Australia) or nominated by cases, and were frequency-
matched to cases by city, age and sex. 
 
The Leeds Melanoma Case-Control Study is a population-based case-control study.12 Data 
were collected using self-administered and telephone administered questionnaires, and skin 
examinations were conducted by research nurses on 960 incident first-primary cutaneous 
melanoma cases and 513 controls from Yorkshire, United Kingdom. Cases, diagnosed 
between September 2000 and December 2005 at ages 18-76 years, were identified from 
clinicians, pathology registers and cancer registries. Controls were identified from the cases’ 
general practice (usually the practice nearest to their home residence), and were frequency-
matched to cases by age and sex.  
 
Model Development 
The model was developed with the Australian study data.11 All relevant candidate predictors 
were included: demographic factors- age, sex, city of recruitment; clinically-assessed factors- 
total number of naevi ≥2mm diameter, number of raised naevi ≥2mm in diameter,  number of 
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dysplastic naevi ≥2mm in diameter, and solar lentigines on the upper back (based on a 6-level 
pictogram); and self-assessed risk factors- freckle density (based on 6-level pictogram), 
country of birth, ethnicity, skin colour, eye colour, natural hair colour at age 18 years, skin 
response to sunlight, height, weight, blistering sunburn frequency (childhood, lifetime), 
sunbed use, sunscreen use, personal history of non-melanoma skin cancer and first-degree 
family history of melanoma. Previous studies have shown fair to moderate agreement 
between clinically- and self-assessed skin colour, and good agreement between clinically-and 
self-assessed eye colour and hair color.9 We have previously shown that a ‘pigmentation 
phenotype score’ derived from self-assessed risk factors comprising childhood freckling, skin 
colour, eye colour, hair colour, ability to tan and propensity to sunburn, gave the same 
improvement to discrimination in a melanoma risk prediction model as did a pigmentation 
phenotype score that incorporated clinically-assessed skin reflectance, eye colour and hair 
colour (incremental improvement to the AUC was 0.053 for the self-assessed score and 0.047 
for the clinically-assessed score).10 For this reason we selected self-assessed pigmentation 
phenotype risk factors because it is more efficient and less costly for patients to complete risk 
factor information in the waiting room than for the clinician to complete during the 
consultation. However, it was important to include clinically-assessed naevi and solar 
lentigines in the risk prediction model as these are usually more difficult for patients to assess 
and our previous study showed that clinical assessment of naevi and solar lentigines gave 
much higher improvement in the AUC than self-assessed naevi (incremental improvement to 
the AUC was 0.048 for self-assessed naevi, 0.111 for clinically-assessed naevi and 0.063 for 
clinically-assessed solar lentigines).10  
 
We used unconditional logistic regression with backward selection in which the study design 
variables age, sex and city of recruitment were kept in each step and other variables with p-
Paper_short report_model incorporating clinical risk factors_final 7 
values >0.05 were removed. Effect modification was tested by adding terms for the 
interaction between pairs of variables in the final model. Multiple imputation by chained 
equations with 10 imputed datasets was used to impute missing values.13 
 
Relative risks and odds per age- and sex-adjusted standard deviation (OPERA)14 were 
calculated as a way of comparing the predictive strengths , in terms of differentiating cases 
from controls, for variables included in the final model. As described elsewhere,15 r maining 
lifetime (to 85 years of age) absolute risk was estimated using the Gail method16 by 
combining relative risks with Australian melanoma incidence and competing mortality rates 
(Online Table 1).  
 
Model performance and validation 
The model was internally validated with the Australian study and externally validated with 
the Leeds study data.11, 12 We assessed discrimination, the model’s ability to distinguish 
between individuals with and without melanoma, using the area under curve (AUC).17 In age 
and sex-matched case-control studies, the distributions of risk factors among controls may be 
more similar to cases than the general population;18 we therefore reweighted the age and sex 
distribution of the control participants to the general population (Online Method 1). Bootstrap 
procedures were used with 1000 repetitions to estimate the 95% confidence intervals. 
 
We assessed overall calibration, the agreement between the model’s predicted and observed 
risk, using the Hosmer-Lemeshow (H-L) test, where the predicted and observed risks of 
melanoma were compared across deciles of predicted risk using a chi-square test, and a high 
test p-value indicates good overall calibration.17 The predicted risk was applied to the logistic 
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regression model as a fixed term, while the intercept could vary to account for the higher 
proportion with melanoma in the case-control studies. 
 
The same variables were used in both studies except for solar lentigines, which was not 
measured in the Leeds study. Instead, we used freckle density as a proxy for solar lentigines 
in the Leeds analysis, as there was moderate agreement between these variables in the 
Australian study (Spearman correlation coefficient=0.28, 95% CI 0.21-0.35, p<0.001). Leeds 
study participants with missing values for any of the predictor variables were excluded. 
Online Table 2 shows the distributions of the predictor variables in the analyses. 
 
Ethical approvals were obtained from the University of Sydney and the relevant UK Multi 
Centre Ethics Committee (MREC)  and Patient Information Advisory Group (PIAG). All 
participants gave written informed consent. Statistical analyses were conducted using Stata 
version 12 for model development and SAS version 9.3 for model validation. Two-sided 
statistical significance was inferred at p<0.05, except for interaction terms where p<0.01 was 
used to allow for multiple testing.19 We report methods and results in accordance with the 




The final model included the total number of naevi ≥2mm, solar lentigines on the upper back, 
hair colour at age 18 years and personal history of non-melanoma skin cancer. There were no 
significant interactions between pairs of variables in the final model. Relative risk and 
OPERA estimates are shown for both studies in Table 2, the number of body naevi ≥2mm in 
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diameter was by far the strongest predictor in terms of differentiating cases from controls on 
a population basis.  
  
The AUC was 0.79 (95% CI 0.76-0.83) on internal validation in the Australian study and was 
0.73 (95% CI 0.70-0.75) on external validation in the Leeds study. The AUC did not increase 
when the age and sex distribution was reweighted to the general population (Online Table 3). 
The H-L test p-value was 0.30 on internal validation and <0.001 on external validation. 
Figure 1 shows that the poor calibration for the Leeds study was due to the model under-
estimating risk at lower risk levels and over-estimating risk at higher levels. In sensitivity 
analyses, calibration in the Leeds study did not improve when we re-calculated lifetime 
absolute risks using Leeds incidence and mortality rates, or when using naevus quartile cut-
points based on the Leeds rather than Australian dataset (results not shown). 
 
Discussion 
This melanoma risk prediction model incorporating clinically-assessed naevi and solar 
lentigines had good discrimination that was maintained on external validation; and good 
overall calibration internally but less so externally. Consistent with previous melanoma risk 
prediction models, we observed higher melanoma risks and greater predictive strength from 
naevus counts equivalent to 10-20 fold interquartile risk ratios.8 Solar lentigines mostly arise 
from prolonged sun exposure, and are a recognised melanoma risk factor,21 but have not been 
included in previous models.8  
 
This model’s discrimination compares well with previous melanoma risk prediction models, 
which reported AUCs from 0.62 to 0.93, although most of these were not externally 
validated.8, 22, 23 There is higher discriminative performance for models using clinically-
Paper_short report_model incorporating clinical risk factors_final 10 
assessed than self-assessed dermatologic risk factors such as naevus counts, probably because 
they are more accurately measured by clinicians.9 Our previous model using only self-
assessed risk factors15 reported lower AUCs, ranging from 0.63 to 0.70 on external 
validation, although this can be improved by incorporating data on common genomic 
variants.24 The low p-value for the H-L test indicated poor overall calibration on external 
validation. Although the model was very good at discriminating melanoma risk level across 
both studies, the personal lifetime absolute risk estimates were less accurate in the Leeds 
study. However, in the absence of cohort studies with clinically-assessed melanoma risk 
factors, we were unable to estimate absolute measures of calibration or evaluate net benefit. 
 
Strengths of our study include the multi-centred, population-based design, comprehensive 
assessment of risk factors and inclusion of clinically-assessed dermatologic risk factors in the 
model development and external validation. The Australian and Leeds study shared 
measurement protocols to ensure that risk factors were measured consistently across the 
studies and that clinical assessments were conducted with the same protocol. We used robust 
statistical approaches, including multiple imputation to impute missing data and external 
validation of the model in an independent population.  
 
A limitation was the use of freckle density as a proxy for solar lentigines in the Leeds study. 
Although there was moderate correlation between freckle density and solar lentigines, solar 
lentigines were a stronger predictor than freckle density in the Australian study; thus the 
estimated external validation discriminative performance is probably an underestimate. Other 
potential limitations of case-control studies include possible selection bias and recall bias.11 
 
Paper_short report_model incorporating clinical risk factors_final 11 
In summary, this melanoma risk prediction model incorporating clinically-assessed risk 
factors has good discrimination, with ability to distinguish between individuals with and 
without melanoma across two populations with different ambient sun exposure. The model 
may be useful for offering tailored preventive interventions such as sun protection advice and 
skin screening based on personal risk level, in primary care and other clinical settings where 
dermatologic risk factors can be assessed. Prospective evaluation of the clinical risk 
prediction model will be important to estimate absolute calibration, net benefit, cost-
effectiveness, and impact on risk behaviours or melanoma outcomes.
Paper_short report_model incorporating clinical risk factors_final 12 
 
Acknowledgement 
Author Contributions  
Drs Vuong and McGeechan had full access to all of the data in the study and take 
responsibility for the integrity of the data and the accuracy of the data analysis. Study concept 
and design: Vuong, Armstrong, Cust and McGeechan. Acquisition, analysis, and 
interpretation of data: All authors. Drafting of the manuscript: Vuong. Critical revision of 
the manuscript for important intellectual content: All authors. Statistical analysis: Vuong, 
McGeechan and Davis. Obtained funding: Vuong and Cust. Study supervision: Armstrong, 
Cust and McGeechan. 
 
Funding/Support  
Kylie Vuong was supported by a University of Sydney Postgraduate Scholarship in Cancer 
Epidemiology (funded through a Cancer Institute NSW fellowship to AEC) and a Sydney 
Catalyst Top-Up Research Scholar Award. Anne E Cust was supported by fellowships from 
the Cancer Institute NSW (15/CDF/1-14) and the National Health and Medical Research 
Council (NHMRC) (1147843). The studies received funding from the NHMRC (project 
grants 107359, 211172 and Program Grant 402761 to GJM); project grants from the Cancer 
Councils New South Wales (77/00, 06/10), Victoria and Queensland (371); the US National 
Institutes of Health (via RO1 grant CA-83115 to the international Melanoma Genetics 
Consortium, GenoMEL, www.genomel.eu); and Cancer Research UK (Project Grant 
C8216/A6129 and Programme awards C588/A4994, C588/A10589 and C588/A19167).  
 
Role of the Sponsors 
Paper_short report_model incorporating clinical risk factors_final 13 
The sponsors had no role in the design and conduct of the study; in the collection, analysis, 
and interpretation of data; or in the preparation, review, or approval of the manuscript, or 
decision to submit the manuscript for publication. 
 
Financial Disclosure of the Authors  
None reported.
Paper_short report_model incorporating clinical risk factors_final 14 
 
References 
 1. Erdmann F, Lortet-Tieulent J, Schuz J, Zeeb H, Greinert R, Breitbart EW, Bray F. 
International trends in the incidence of malignant melanoma 1953-2008- are recent 
generations at higher or lower risk? International Journal of Cancer 2013;132: 85-400. 
 2. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Picconi O, Boyle P, Melchi CF. 
Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 
2005;41: 45-60. 
 3. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Abeni D, Boyle P, Melchi CF. 
Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. 
European Journal of Cancer 2005;41: 28-44. 
 4. Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P, 
Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic 
damage and phenotypic factors. European Journal of Cancer 2005;41: 2040-59. 
 5. Fang S, Han J, Zhang M, Wang LE, Wei Q, Amos CI, Lee JE. Joint effect of 
multiple common SNPs predicts melanoma susceptibility. PLoS One 2013;8: e85642. 
 6. RACGP. Guidelines for preventive activities in general practice, 9th ed. East 
Melbourne, Victoria: The Royal Australian College of General Practitioners, 2016. 
 7. Freedman A, Seminara D, Mitchell G, Hartge P, Colditz G, Ballard-Barbash R, 
Pfeiffer R. Cancer risk prediction models: a workshop on development, evaluation and 
application. Journal of the National Cancer Institute 2005: 715-23. 
 8. Vuong K, McGeechan K, Armstrong BK, Cust AE. Risk prediction models for 
incident primary cutaneous melanoma: a systematic review. JAMA Dermatol 2014;15 : 34-
44. 
 9. Cust AE, Pickles KM, Goumas C, Vu T, Schmid H, Nagore E, Kelly J, Aitken JF, 
Giles GG, Hopper JL, Jenkins MA, Mann GJ. Accuracy of self -reported nevus and 
pigmentation phenotype compared with clinical assessment in a population-based study of 
young Australian adults. Cancer Epidemiol Biomarkers Prev 2015;4: 736-43. 
 10. Cust AE, Goumas C, Vuong K, Davies JR, Barrett JH, Holland EA, Schmid H, 
Agha-Hamilton C, Armstrong BK, Kefford RF, Aitken JF, Giles GG, et al. MC1R genotype 
as a predictor of early-onset melanoma, compared with self-reported and physician-measured 
traditional risk factors: an Australian case-control-family study. BMC Cancer 2013;13: 406. 
 11. Cust AE, Schmid H, Maskiell JA, Jetann J, Ferguson M, Holland EA, Agha-
Hamilton C, Jenkins MA, Kelly J, Kefford RF, Giles GG, Armstrong BK, et al. Population-
based, case-control-family design to investigate genetic and environmental influences on 
melanoma risk: Australian Melanoma Family Study. Am J Epidemiol 2009;17 : 1541-54. 
Paper_short report_model incorporating clinical risk factors_final 15 
 12. Newton-Bishop JA, Chang YM, Iles MM, Taylor JC, Bakker B, Chan M, Leake 
S, Karpavicius B, Haynes S, Fitzgibbon E, Elliott F, Kanetsky PA, et al. Melanocytic nevi, 
nevus genes, and melanoma risk in a large case-control study in the United Kingdom Cancer 
Epidemiol Biomarkers Prev, 2010; 19: 2043-54. 
 13. Vergouwe Y, Royston P, Moons KG, Altman DG. Development and validation of 
a prediction model with missing predictor data: a practical approach J Clin Epidemiol, 2010; 
63: 205-14. 
 14. Hopper JL. Odds per adjusted standard deviation: comparing strengths of 
associations for risk factors measured on different scales and across diseases and populations. 
Am J Epidemiol 2015;182: 863-7. 
 15. Vuong K, Armstrong BK, Weiderpass E, Lund E, Adami HO, Veierod MB, 
Barrett JH, Davies JR, Bishop DT, Whiteman DC, Olsen CM, Hopper JL, et al. Development 
and External Validation of a Melanoma Risk Prediction Model Based on Self-assessed Risk 
Factors. JAMA Dermatol 2016;152: 889-96. 
 16. Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ. 
Projecting individualized probabilities of developing breast cancer for white females who are 
being examined annually. Journal of the National Cancer Institute 1989;81: 1879-86. 
 17. Steyerberg EW. Clinical prediction modelsed. New York: Springer, 2010. 
 18. Pepe MS, Fan J, Seymour CW, Li C, Huang Y, Feng Z. Biases introduced by 
choosing controls to match risk factors of cases in biomarker research Clin Chem, 2012; 58: 
1242-51. 
 19. Bender R, Lange S. Adjusting for multiple testing—when and how? Journal of 
Clinical Epidemiology 2001;54: 343-9. 
 20. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a 
multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD 
statement. Bmj 2015;350: g7594. 
 21. Kvaskoff M, Siskind V, Green AC. Risk factors for lentigo maligna melanoma 
compared with superficial spreading melanoma: a case-control study in Australia. Arch 
Dermatol 2012;148: 164-70. 
 22. Olsen CM, Pandeya N, Thompson BS, Dusingize JC, Webb PM, Green AC, Neale 
RE, Whiteman DC. Risk Stratification for Melanoma: Models Derived and Validated in a 
Purpose-Designed Prospective Cohort. J Natl Cancer Inst 2018. 
 23. Olsen CM, Neale RE, Green AC, Webb PM, the QS, the Epigene S, Whiteman 
DC. Independent Validation of Six Melanoma Risk Prediction Models. J Invest Dermatol 
2015;135: 1377-84. 
 24. Cust AE, Drummond M, Kanetsky PA, Goldstein AM, Barrett JH, MacGregor S, 
Law MH, Iles MM, Bui M, Hopper JL, Brossard M, Demenais F, et al. Assessing the 
Paper_short report_model incorporating clinical risk factors_final 16 
incremental contribution of common genomic variants to melanoma risk prediction in two 
population-based studies. J Invest Dermatol 2018;8: 32046-3. 
 25. Bruzzi P, Green SB, Byar DP, Brinton LA, Schairer C. Estimating the population 
attributable risk for multiple risk factors using case-control data. American Journal of 
Epidemiology 1985;122: 904-14. 
Paper_short report_model incorporating clinical risk factors_final 17 
Table 1. Summary of the Australian Melanoma Family Study (development dataset) and Leeds Melanoma Case-Control Study (external 
validation dataset) 
 






























































Skin examinations by 





a Population-based controls were identified from the electoral roll and frequency-mat hed to cases by geographical location, age and sex; and spouse/friend controls were 
nominated by the cases. 
b Controls were identified from the cases' general practice patient lists and were frequ ncy-matched to cases by age and sex.
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Table 2.  Relative risk estimatesa and odds per adjusted standard deviation (OPERA)b for the 
multivariable melanoma risk prediction model on the Australian Melanoma Family Study 




a Odds ratios were used to estimate relative risks, and were adjusted for all other variables in the model as well 
as age, sex and city of recruitment. 
b The OPERA scores are calculated for variables included in the prediction model to enable comparison of the 
predictive strengths, in terms of ability to differentiate cases from controls, of the risk factors across different 
diseases and populations using the formula OPERA= exp [In (RR)/A]=RRs; where RR is relative risk, and A=1/s 
adjusted standard deviations.14 The standard deviations were adjusted for age (in 5 year intervals) and sex using 
the control data. Given the difference between the upper and lower quartiles of a normal distribut on is 
approximately 2.54 standard deviations, the estimated OPERA risk gradients ar  equivalent to interquartile risk 




Risk factor in the modelc Relative riska (95% CI) Relative riska (95% CI) 
Total number of whole-
body naevi ≥2mm 
diametere,f 
  
    
< 28 1.00 1.00 
28-61 3.10 (1.47 -  6.53) 2.88 (2.15 – 3.86) 
62-143 6.74 (3.32 - 13.67) 6.28 (4.18 - 9.43) 
More than 144 20.03 (9.76 - 41.09) 28.72 (8.79 – 93.81) 
Solar Lentigines on upper 
backd,e   
 <20% 1.00 1.00 
20% 1.41 (0.68 - 2.92) 2.71 (1.70- 4.31) 
40% 2.08 (0.97 - 4.46) 2.43 (1.52 – 3.87) 
60% 2.81 (1.25 - 6.29) 2.20 (1.34 – 3.61) 
80% 3.08 (1.40 - 6.76) 2.34 (1.36 – 4.03) 
100% 3.49 (1.29 - 9.41) 0.77 (0.35 -1.67) 
Hair colour at age 18    
 Black/ dark brown 1.00 1.00 
Light brown 1.22 (0.80 - 1.85) 1.62 (1.19 – 2.20) 
Blonde 2.29 (1.30 - 4.03) 2.46 (1.64 – 3.68) 
Red 3.29 (1.39 - 7.78) 4.17 (2.45 – 7.09) 
Personal history of non-
melanoma skin cancer    
No 1.00  
Yes 9.76 (2.09 – 45.54) 1.31 (0.56 - 3.04) 
Analysed as OPERAsb Odds ratio 
(95% CI)  
P value  Odds ratio (95% 
CI) 
P value  
Total number of body naevi 
≥2mm diameter e,f 
 3.51 (2.71-4.54) <0.001 2.56 (2.23-2.95) <0.0001 
Solar Lentigines on upper 
back d,e 
1.50 (1.19-1.89)  0.001 0.95 (0.83-1.08) 0.41 
Hair colour at age 18 years 1.37 (1.15-1.63) 0.001 1.44 (1.27-1.64) <0.0001 
Personal history of non-
melanoma skin cancer 
1.12 (0.93-1.34) 0.236 0.98 (0.87-1.11) 0.81 
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ratios of 3.512.54 ~ 24 (95% CI 13-47) for the total number of body naevi ≥ 2mm diameter, 1.502.54 ~ 2.8 (95% CI 
1.6-5.0) for solar lentigines on the upper back, 1.372.54 ~ 2.2 (95%CI 1.4 -3.5) for hair colour at age 18 years, 
and 1.122.54 ~ 1.3 (95% CI 0.8 – 2.1) for personal non-melanoma skin cancer. 
c The model intercept was 0.53 (95% CI 0.05 - 5.79) and attributable frction, as calculated from the distribution 
of relative risk among the cases,25 was 0.96 (95% CI 0.95-0.97). 
d In the Leeds Melanoma Case-Control Study, freckle density categorized by the cut points 20%, 40%, 60%, 
80%, 100% was used as a proxy for solar lentigines (Spearman correlation coefficient=0.28, 95% CI 0.21- 0.35, 
p<0.0001). 
e Assessed from clinical examinations in dermatology clinics.  
f Based on quartile cut-points in the Australian Melanoma Family Study controls. 
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Figure Legends 
Figure 1. Observed versus predicted risk of incident melanomas across on internal and 
external validation. This graph compares the observed and predicted risk of incident 
melanomas on internal validation in the Australian Melanoma Family Study (blue line) and 
on external validation in the Leeds Melanoma Case-Control Study (orange line), with perfect 
overall calibration (black line). 
 
